Search clinical trials for: cobimetinib

Total 119 results

Inova Health Care Services
Genentech, Inc.

Withdrawn

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Stage IIIB-C Melanoma

United States
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
Melissa Burgess, MD
Genentech, Inc.

Terminated

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases (CoBRIM-B)

Active Melanoma Brain Metastases

United States
Genentech, Inc.

Completed

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

Healthy Volunteers
Genentech, Inc.

Completed

A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants

Healthy Volunteer
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Genentech, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Withdrawn

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Melanoma

United States
Genentech, Inc.

Completed

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Healthy Volunteer

United States
Hoffmann-La Roche

Withdrawn

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Neoplasms

United States
Genentech, Inc.

Completed

Study of Cobimetinib in Participants With Solid Tumors

Solid Tumor

United States
Genentech, Inc.

Completed

A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants

Healthy Participants

United States
Genentech, Inc.

Completed

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

Healthy Volunteer

United States
Astellas Pharma Inc

Terminated

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Aspergillosis

United States
University Hospital, Toulouse

Completed

Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy (PTCRRT)

Diffusive and Convective Clearance | Body Clearance | Piperacillin Tazocilline Concentrations (Cmin)

France
Children's Hospital Medical Center, Cincinnati
Astellas Pharma Inc

Completed

Alternate Day Micafungin: A PK Study in Pediatric Patients

Fungal Infection

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Hematologic Neoplasms

United States, Canada

3

Subscribe